Recurrent Soft Tissue Sarcoma Recruiting Phase 2 Trials for Tipifarnib (DB04960)

IndicationStatusPhase
DBCOND0105100 (Recurrent Soft Tissue Sarcoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04284774Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialTreatment
NCT03155620Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Screening